medigraphic.com
ISSN 1561-2996 (Digital)
ISSN 0864-0289 (Impreso)

2021, Número 4

<< Anterior Siguiente >>

Rev Cubana Hematol Inmunol Hemoter 2021; 37 (4)


Linfoma difuso de células grandes B CD5 positivo con compromiso prostático: una recurrencia inusual

Castro UDA, Tarazona LDS, Mendoza CR, Beltrán GBE

Idioma: Español
Referencias bibliográficas: 39
Paginas: 1-12
Archivo PDF: 448.16 Kb.


RESUMEN

Introducción: El Linfoma de células grandes B CD5 positivo (LDCGB CD5+) constituye una patología rara y agresiva con pobre respuesta a la quimioinmunoterapia.
Objetivo: Describir un caso con diagnóstico de LDCGB CD5+ con recurrencia inusual prostática.
Caso clínico: Paciente varón de 61 años con sintomatología de dolor abdominal y síntomas B. Los estudios de imagen mostraron adenopatías mediastinales y retroperitoneales. El informe patológico fue compatible LDCGB CD5+, recibiendo terapia de primera línea con R-CHOP logrando remisión completa, con recaída precoz prostática confirmada por inmunohistoquímica. Posteriormente, inicia terapia de rescate con R-ICE, con pobre respuesta y deterioro del estado funcional.
Conclusiones: El LDCGB CD5 + representa una patología infrecuente y agresiva, siendo la recaída en próstata un evento muy inusual, es por ello que los exámenes clínicos exhaustivos y anatomo-patológico son esenciales para un diagnóstico certero. A la fecha, la respuesta a terapias estándar o de mayor intensidad son desalentadoras, por lo que es necesario un mayor número de estudios a futuro.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Liu Y, Barta SK. Diffuse large B-cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment. Am J Hematol. 2019 May; 94(5):604-16. DOI : https://10.1002/ajh.25460

  2. Padilla Valdez JJ, Ulloa Pérez V, Venegas Ojeda D. Características epidemiológicas, clínicas y patológicas de los linfomas en el Hospital Nacional Cayetano Heredia del año 1998 al 2008. Acta Médica Perú. 2011;28(1):12-8.

  3. Registro de Cáncer de Lima Metropolitana. Incidencia y Mortalidad 2010 - 2012, Volumen 5. Lima 2016. [acceso 06/10/2020 ]Disponible en:https://portal.inen.sld.pe/registro-de-cancer-en-lima-metropolitana/

  4. Castañeda-Ruiz P, Via y Rada F, Serra-Jaramillo R, Paz-Cornejo E, Salas-Sánchez F. Linfoma difuso de células B grandes: ¿una sola enfermedad? Rev Perú Med Exp Salud Publica. 2017; 34(3):551. DOI: https://10.17843/rpmesp.2017.343.2803

  5. Jain P, Fayad LE, Rosenwald A, Young KH, O'Brien S. Recent advances in de novo CD5+ diffuse large B cell lymphoma. Am J Hematol. 2013 Sep; 88(9):798-802. DOI : https://10.1002/ajh.23467

  6. Xu Y, Sun W, Li F. De Novo CD5+ Diffuse Large B-Cell Lymphoma: Biology, Mechanism, and Treatment Advances. Clin Lymphoma Myeloma Leuk. 2020 Oct; 20(10):782-90. DOI : https://10.1016/j.clml.2020.05.003

  7. Villacis-Fonseca, Garcia Martinez, Carbajal-García R, Sahagún-Flores JE G-HR. Linfoma primario de célula B grande de próstata. Comunicación de un caso. Rev Espec Médico-Quirúrgicas. 2012;17(1):56-9.

  8. Sørensen JB, Klee M, Palshof T, Hansen HH. Performance status assessment in cancer patients. an inter-observer variability study. Br J Cancer. 1993;67(4):773-5.

  9. A Predictive Model for Aggressive Non-Hodgkin's Lymphoma. N Engl J Med. 1993;329(14):987-94.

  10. Zhou Z, Sehn LH, Rademaker AW, Gordon LI, LaCasce AS, Crosby-Thompson A, et al. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood. 2014;123(6):837-42.

  11. Cabanillas F, Shah B. Advances in Diagnosis and Management of Diffuse Large B-cell Lymphoma. Clin Lymphoma Myeloma Leuk. 2017; 17(12):783-96. DOI : https://10.1016/j.clml.2017.10.007

  12. Xu-Monette ZY, Tu M, Jabbar KJ, Cao X, Tzankov A, Visco C, et al. Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countries. Oncotarget. 2015;6(8):5615-33.

  13. Kong SY, Cho EH, Woo HY, Park Q, Ko YH, Kim SH. De novo CD5 positive diffuse large B-cell lymphomas with bone marrow involvement in Korean. J Korean Med Sci. 2004;19(6):815-9.

  14. Thakral B, Medeiros LJ, Desai P, Lin P, Yin CC, Tang G, et al. Prognostic impact of CD5 expression in diffuse large B-cell lymphoma in patients treated with rituximab-EPOCH. Eur J Haematol. 2017;98(4):415-21. DOI : https://10.1111/ejh.12847

  15. Rioja Zuazu J, Iglesias R, Rosell Costa D, Rincón Mayans A, Brugarolas i Roselló X, Panizo Santos Á, et al. Linfoma prostático y revisión de la literatura. Actas Urológicas Españolas. 2009;33(6):686-90.

  16. Terris MK, Hausdorff J, Freiha FS. Hematolymphoid malignancies diagnosed at the time of radical prostatectomy. J Urol. 1997;158(4):1457-9.

  17. Igawa T, Sato Y, Takata K, Iwaki N, Tanaka T, Asano N, et al. De novo CD5-positive diffuse large B-cell lymphomas show high specificity for cyclin D2 expression. Diagn Pathol. 2013;8(1). DOI: https://doi.org/10.1186/1746-1596-8-81

  18. Yamaguchi M, Nakamura N, Suzuki R, Kagami Y, Okamoto M, Ichinohasama R, et al. De novo CD5+ diffuse large B-cell lymphoma: Results of a detailed clinicopathological review in 120 patients. Haematologica. 2008;93(8):1195-202.

  19. Chuang WY, Chang H, Shih LY, Wang PN, Chang YS, Lin TL, et al. CD5 positivity is an independent adverse prognostic factor in elderly patients with diffuse large B cell lymphoma. Virchows Arch. 2015;467(5):571-82.

  20. Lossos IS, Czerwinski DK, Alizadeh AA, Wechser MA, Tibshirani R, Botstein D, et al. Prediction of Survival in Diffuse Large-B-Cell Lymphoma Based on the Expression of Six Genes. N Engl J Med. 2004;350(18):1828-37.

  21. Zhao P, Li L, Zhou S, Qiu L, Qian Z, Liu X, et al. CD5 expression correlates with inferior survival and enhances the negative effect of p53 overexpression in diffuse large B-cell lymphoma. Hematol Oncol. 2019; 37(4):360-7. DOI : https://10.1002/hon.2657

  22. Ma X bo, Zhong Y ping, Zheng Y, Jiang J, Wang Y ping. Coexpression of CD5 and CD43 predicts worse prognosis in diffuse large B-cell lymphoma. Cancer Med. 2018; 7(9):4284-95. DOI : https://10.1002/cam4.1674

  23. Na HY, Choe JY, Shin SA, Kim HJ, Han JH, Kim HK, et al. Characteristics of CD5-positive diffuse large Bcell lymphoma among Koreans: High incidence of BCL2 and MYC doubleexpressors. PLoS One. 2019 Oct 23;14(10):e0224247. DOI : https://10.1371/journal.pone.0224247

  24. Gary-Gouy H, Harriague J, Bismuth G, Platzer C, Schmitt C, Dalloul AH. Human CD5 promotes B-cell survival through stimulation of autocrine IL-10 production. Blood. 2002; 100(13):4537-43.

  25. Woznialis N, Gierej B, Poplawska L, Ziarkiewicz M, Wolinska E, Kulczycka E, et al. Angiogenesis in CD5-positive diffuse large B cell lymphoma: A morphometric analysis. Adv Clin Exp Med. 2016; 25(6):1149-55. DOI : https://10.17219/acem/61427

  26. Cheah CY, Seymour JF, Wang ML. Mantle cell lymphoma. J Clin Oncol. 2016 Apr 10;34(11):1256-69. DOI : https://10.1200/JCO.2015.63.5904

  27. Mozos A, Royo C, Hartmann E, De Jong D, Baró C, Valera A, et al. SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype. Haematologica. 2009; 94(11):1555-62.

  28. Rossi D, Spina V, Gaidano G. Biology and treatment of Richter syndrome. Blood. 2018; 131(25):2761-72. DOI : https://10.1182/blood-2018-01-791376

  29. Ponzoni M, Campo E, Nakamura S. Intravascular large B-cell lymphoma: A chameleon with multiple faces and many masks. Blood. 2018 Oct 11;132(15):1561-1567. DOI : https://10.1182/blood-2017-04-737445

  30. Hallek M. Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment. Am J Hematol. 2019; 94(11):1266-87. DOI : https://10.1002/ajh.25595

  31. Kim HY, Jang MA, Kim HJ, Kim SJ, Kim WS, Kim SH. Clinical impact of CD5 expression in Korean patients with diffuse large B-cell lymphoma. Blood Res. 2017; 52(3):193-9. DOI : https://10.5045/br.2017.52.3.193

  32. Ennishi D, Takeuchi K, Yokoyama M, Asai H, Mishima Y, Terui Y, et al. CD5 expression is potentially predictive of poor outcome among biomarkers in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy. Ann Oncol. 2008; 19(11):1921-6.

  33. Tang H, Zhou H, Wei J, Liu H, Qian W, Chen X. Clinicopathologic significance and therapeutic implication of de novo CD5+ diffuse large B-cell lymphoma. Hematol (United Kingdom). 2019; 24(1):446-54. DOI : https://10.1080/16078454.2019.1614289

  34. Hyo R, Tomita N, Takeuchi K, Aoshima T, Fujita A, Kuwabara H, et al. The therapeutic effect of rituximab on CD5-positive and CD5-negative diffuse large B-cell lymphoma. Hematol Oncol. 2010; 28(1):27-32.

  35. Niitsu N, Okamoto M, Tamaru JI, Yoshino T, Nakamura N, Nakamura S, et al. Clinicopathologic characteristics and treatment outcome of the addition of rituximab to chemotherapy for CD5-positive in comparison with CD5-negative diffuse large B-cell lymphoma. Ann Oncol. 2010; 21(10):2069-74.

  36. Zhang F, Li L, Zhang L, Li X, Fu X, Wang X, et al. Prognostic analysis of CD5 expression in double-hit diffuse large B-cell lymphoma and effectiveness comparison in patients treated with dose-adjusted EPOCH plus rituximab/R-CHOP regimens. Blood Lymphat Cancer. 2019 Aug;9:33-43. DOI : https://10.2147/BLCTT.S216292

  37. Miyazaki K, Asano N, Yamada T, Miyakawi K, Sakai R, Igarachi T, et al. DA-EPOCH-R combined with high-dose methotrexate for newly diagnosed CD5-positive diffuse large b-cell lymphoma. Hematol Oncol. 2020; 105(9):2308-2315. DOI : https://10.3324/haematol.2019.231076

  38. Alinari L, Gru A, Quinion C, Huang Y, Lozanski A, Lozanski G, et al. De novo CD5+ diffuse large B-cell lymphoma: Adverse outcomes with and without stem cell transplantation in a large, multicenter, rituximab treated cohort. Am J Hematol. 2016; 91(4):395-9. DOI : https://10.1002/ajh.24299

  39. Zhang Y, Wang X, Liu Y, Sun C, Shi W, Huang H. Lenalidomide combined with R-GDP in a patient with refractory CD5-positive diffuse large B-cell lymphoma: A promising response and review. Cancer Biol Ther. 2018; 19(7):549-53. DOI : https://10.1080/15384047.2018.1449609




2020     |     www.medigraphic.com